|
Table 1: Characteristics of eligible studies and clinical and functional results. |
||||||||
|
Study |
Year |
Patients /feet |
Mean age (years) |
Sex male / female |
Stage |
Treatment |
Follow-up (months) |
Outcome |
|
Nurmukhametov MR, et al6 |
2021 |
19/19 |
48.0 |
4/15 |
3 feet/II 11 feet/III 5 feet/IV |
AMIC |
12 |
VAS (1.5) FFI (1) AOFAS (92.5) ROM (71.5o) |
|
Richter M10 |
2021 |
176/176 |
52.6 |
28/148 |
II* |
AMIC + PBC |
24 |
VASFA (74.1) EFAS (17.1) |
|
Nurmukhametov MR, et al9 |
2021 |
15/21 |
55.0 |
5/16 |
1 feet/I 3 feet/II 11 feet/III 6 feet/IV |
AMIC |
12 |
VAS (1) AOFAS (87.5) ROM (71.5o) |
|
Richter M, et al11 |
2022 |
154/154 |
57.6 |
28/126 |
II* |
AMIC + PBC |
60 |
VASFA (75) EFAS (17.3) |
|
Nurmukhametov MR, et al12 |
2020 |
15/16 |
42.2 |
– |
I/II |
AMIC |
12 |
AOFAS (90) VASFA (9.6) ROM (67.5o) FFI (1.2) |
|
AMIC = autologous matrix induced chondrogenesis. AOFAS = American Orthopaedic Foot and Ankle Society. EFAS = European Society for Foot and Ankle Surgery. ROM = range of motion. PBC = peripheral blood concentrate. VAS = visual analog scale. VASFA = visual analog scale foot and ankle. * Studies did not classify all patients and most of them were stage II. |
||||||||